Avidity heads to FDA with exon 44 skipping Duchenne muscular dystrophy drug
Avidity Biosciences shared Monday that its RNA drug for people with certain mutations of Duchenne muscular dystrophy continued to show strong results as it completed an early-phase study, and the biotech is planning to apply ...
Avidity Biosciences shared Monday that its RNA drug for people with certain mutations of Duchenne muscular dystrophy continued to show strong results as it completed an early-phase study, and the biotech is planning to apply ...
